IXICO (LSE:IXI) 3-Year Revenue Growth Rate

: -11.60% (As of Sep. 2023)

View and export this data going back to 1996. Start your Free Trial

IXICO's Revenue per Share for the six months ended in Sep. 2023 was £0.07.

During the past 12 months, IXICO's average Revenue per Share Growth Rate was -18.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was -11.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -2.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 44.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of IXICO was 433.70% per year. The lowest was -80.20% per year. And the median was 1.60% per year.

Competitive Comparison

For the Biotechnology subindustry, IXICO's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO 3-Year Revenue Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, IXICO's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where IXICO's 3-Year Revenue Growth Rate falls into.

IXICO 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

IXICO (LSE:IXI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

IXICO 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of IXICO's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines